



Skeletal Related Events in Metastasis Breast Cancer: Case Report



Ayman Rasmy^{1,2*}, Amal Ameen³ and Mohamed Al-Mashiakhi²

¹Oncology Department, Zagazig University, Zagazig, Egypt

²Oncology Department, King Saud Medical City, Riyadh-KSA

³Microbiology Department, Faculty of Medicine, Fayoum University, Egypt

*Corresponding author: Ayman Rasmy MD, Medical Oncology, Zagazig University, Zagazig-Egypt, Tel: 00966-541899333, Email: ay_rasmy@yahoo.com

Submission: 📅 January 21, 2019; Published: 📅 February 11, 2019

Introduction

Breast cancer is the most common malignancy distressing females in the world. The bone metastases are one of the most common site of disease dissemination. Up to 75% of stage IV Breast cancer patients developing skeletal metastases [1] metastatic bone disease can result in skeletal related events (SREs), including humoral hypercalcaemia of malignancy (HHM), pathological fractures, spinal cord compression, and pain [2]. The median time from bone metastases diagnosis to first SRE can be as short as 1.8 months, with the incidence of SREs growing considerably during the first 12 months following diagnosis [3]. This Bone metastases affect patient survival, movement, and quality of life by negative impact. The molecular mechanisms involved in the metastasis, colonization, and proliferation of breast cancer cells in bone are multifaceted and include crosstalk between breast cancer cells and the bone microenvironment. The capability of metastatic breast cancer cells to capture normal biological processes involved in bone remodeling is a key driver of osteolytic and osteoblastic bone lesions. As such, our understanding of how breast cancer cells manipulate normal bone remodeling pathways is essential for the development of new therapeutic agents to improve patient outcomes.

Case Report

Forty-one years old Female patient, previously medically free, for 4 months start to complain of back pain and left breast lump, pain increased gradually until pt. become unable to bear her weight., she had medical advice outside with only with analgesic prescription for pain. At that time, she had painless breast mass which increased gradually, no nipple discharge, no real or observed disfiguring of breast, recently, she presents to emergency with severe back pain unable to walk or stand. CT spine with contrast done initially found to have multilevel spinal cord compression. During admission she found to have hypercalcemia treated with Calcitonin & Denosumab.

Social history

She is married, lactating mother of one child 2months ago

Family history

No family history of similar condition

Systemic examination

Clinically she conscious, oriented, lying flat in the bed, performance ECOG (3-4) since admission due to back pain Neurology examination showed she had lower limb weakness with power grade 3, upper limb no weakness with constipation and difficulty in urination with catheter. Other system normal examination. Tru-Cut Biopsy was done with pathology full assessment revealed that it diagnosed as IDC, grade II. ER: positive, strong intensity, 80% of tumor cells. PR: negative., HER2: equivocal (2+), sent for FISH. ki-67: less than 5%.

Radiology work up

- i. CT spine Findings suggestive of diffuse osseous metastatic lesion.
 - a) Diffuse destructive changes in the spine with reduced vertebral heights more at T5, and less in T2, T4- T10, L1, L3 and L5 represent multilevel compression fractures.
 - b) Narrowing the spinal canal at level T5 and T6. Also, the posterior element is involved multiple osteolytic lesion in the visualized sternum and ribs.
 - c) Pelvic bones and femora are involved.
- ii. MRI spine: Diffuse bony metastasis
- iii. U/S breast: Suspicious left breast 12 o'clock position mass with abnormal left axillary lymph nodes. BIRADS 5
- iv. CT CAP: Multiple osteolytic and osteoblastic lesions seen in the lumbar and visualized lower dorsal vertebrae with iliac bone involvement and visualized femora. Evidence of moth-eaten lesions seen in the liver parenchyma mainly involving the left lobe segment four and three with focal area involving the segment 6 and 8. There are multiple bony metastasis

Systemic treatments including endocrine therapy, chemotherapy and targeted therapies such as anti-HER2 drugs, mTOR inhibitor, CDK 4/6 inhibitor) can be effective in patients to reduce the burden of bone disease and other disease sites. Glucocorticoids which are commonly used in the symptomatic management of patients with metastatic BC, enhance osteoclasto genesis and reduce osteoclast genesis. Glucocorticoids inhibit OPG and activate RANKL synthesis by pre-osteoblasts to increase osteoclast genesis and stimulate bone resorption [5]. Upon binding of glucocorticoids to glucocorticoid receptors, the receptors tether to the AP-1 site of the interleukin-11 (Il-11) promotor to inhibit Il-11 production, which in turn inhibits osteoblast genesis [6].

There are multiple treating agents currently presented for the managing of metastatic breast cancer to bone by bisphosphonates and RANK/RANKL inhibitors. Numerous novel therapeutic targets are also emerging demonstrating potential clinical utility in the treatment of BC bone metastases, including cathepsin K inhibitors, Src inhibitors, TGF- β blockade, CXCR4 inhibitors, and $\alpha v\beta 3$ integrin antagonists (Figure 2).

References


1. Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, et al. (2013) Incidence: consequences and treatment of bone metastases in breast cancer patients-experience from a single cancer centre. *Journal of Bone Oncology* 2(4): 137-144.
2. Cleeland C, Von MR, Walker MS, Wang Y, Gao J, et al. (2016) Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. *Care Cancer* 24(8): 3557-3565.
3. Jensen A, Jacobsen JB, Nørgaard M, Yong M, Fryzek JP, et al. (2011) Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. *BMC Cancer* 11(1): 29.
4. Coleman RE (1997) Skeletal complications of malignancy. *Cancer* 80(8): 1588-1594.
5. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, et al. (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. *Endocrinology* 140(10): 4382-4389.
6. Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, et al. (2010) Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. *Cell Metab* 11(6): 517-531.



Creative Commons Attribution 4.0 International License

For possible submissions Click Here

Submit Article



Novel Approaches in Cancer Study

Benefits of Publishing with us

- High-level peer review and editorial services
- Freely accessible online immediately upon publication
- Authors retain the copyright to their work
- Licensing it under a Creative Commons license
- Visibility through different online platforms